Alireza Mohebbi

Mr. Alireza Mohebbi

Virology, Iran University of Medical Sciences, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2020 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
EKEsmat Kamali
Esmat Kamali
AJAilar Jamali
Ailar Jamali
AAAbdollah Ardebili
Abdollah Ardebili
FEFreshteh Ezadi
Freshteh Ezadi
Alireza MohebbiAlireza Mohebbi
Alireza Mohebbi
Objectives: Pseudomonas aeruginosa is known as a leading cause of nosocomial infections worldwide. Antimicrobial resistance and biofilm production, as two main virulence factors of P. aeruginosa, are responsible for the persistence of prolonged infections. In this study, antimicrobial susceptibility pattern and phenotypic and genotypic characteristics of biofilm of P. aeruginosa were investigated. Results: A total of 80 clinical P. aeruginosa isolates were obtained. Isolates showed resistance to all antibiotics with a rate from 12.5% (n = 10) against amikacin and piperacillin/tazobactam to 23.75% (n = 19) to levofloxacin. Multidrug-resistant P. aeruginosa accounted for 20% (n = 16). 83.75% (n = 67) of isolates showed biofilm phenotype. All three biofilm-related genes were found simultaneously in 87.5% (n = 70) of P. aeruginosa and 13.5% (n = 10) of the isolates had none of the genes tested. From the results of the present study, combination therapy including an anti-pseudomonal beta-lactam (piperacillin/tazobactam or ceftazidime) and an aminoglycoside or carbapenems (imipenem, meropenem) with fluoroquinolones in conjunction with an aminoglycoside can be used against Pseudomonas infections. However, reasonable antimicrobial use and high standards of infection prevention and control are essential to prevent further development of antimicrobial resistance. Combination strategies based on the proper anti-pseudomonal antibiotics along with anti-biofilm agents can also be selected to eradicate biofilm-associated infections.

17 November 2017 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
SRSanaz Baghban Rahimi
Sanaz Baghban Rahimi
Alireza MohebbiAlireza Mohebbi
Alireza Mohebbi
GVGelareh Vakilzadeh
Gelareh Vakilzadeh
PBPeyvand Biglari
Peyvand Biglari
SJSoodeh Razeghi Jahromi
Soodeh Razeghi Jahromi
AGAmir Ghaemi
Amir Ghaemi

5 April 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
Alireza MohebbiAlireza Mohebbi
Alireza Mohebbi
NLNazanin Lorestani
Nazanin Lorestani
ATAlireza Tahamtan
Alireza Tahamtan
NKNiki L. Kargar
Niki L. Kargar
ATAlijan Tabarraei
Alijan Tabarraei
Current anti-hepatitis B virus (HBV) regimen do not meet ideal result due to emerging resistance strains, cytotoxicity, and unfavorable adverse effects. In chronic HBV infection, high rates of sub-viral particles (SVPs) bearing HBV surface antigen (HBsAg) is a major obstacle regarding to raise effective immune responses and subsequently virus clearance. Development of potent HBsAg secretion inhibitors would provide a better insight into HBV immunopathogenesis and therapy. Investigating new non-toxic HBsAg secretion inhibitors targeting either viral or cellular factors could restore the immune response to remove virally infected hepatocytes after inhibiting SVPs. In this study, we overview several classes of HBV inhibitors with focus on their limitations and advantages over anti-HBsAg secretion potential.

29 February 2024 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
MNMalihe Naderi
Malihe Naderi
ZSZahra Salavatiha
Zahra Salavatiha
UGUrvashee Gogoi
Urvashee Gogoi
Alireza MohebbiAlireza Mohebbi
Alireza Mohebbi
Flavonoids, a diverse group of polyphenolic compounds found in various plant-based foods, have garnered attention for their potential in combating Hepatitis B Virus (HBV) infection. Flavonoids have demonstrated promising anti-HBV activities by interfering with multiple stages of the HBV life cycle, making them promising candidates for novel antiviral agents. Certain plant families, such as Theaceae, Asteraceae, Lamiaceae, and Gentianaceae, are of particular interest for their flavonoid-rich members with anti-HBV activities. Evidences, both in vitro and in vivo, supports the anti-HBV potential of flavonoids. These subsets of compound exert their anti-HBV effects through various mechanisms, including inhibiting viral entry, disrupting viral replication, modulating transcription factors, enhancing the immune response, and inducing autophagy. The antioxidant properties of flavonoids play a crucial role in modulating oxidative stress associated with HBV infection. Several flavonoids like epigallocatechin gallate (EGCG), proanthocyanidin (PAC), hexamethoxyflavone, wogonin, and baicalin have shown significant anti-HBV potential, holding promise as therapeutic agents. Synergistic effects between flavonoids and existing antiviral therapies offer a promising approach to enhance antiviral efficacy and reduce drug resistance. Challenges, including limited bioavailability, translation from preclinical studies to clinical practice, and understanding precise targets, need to be addressed. Future research should focus on clinical trials, combination therapies, and the development of flavonoid derivatives with improved bioavailability, and optimizing their effectiveness in managing chronic HBV infections.


1 June 2021 in Future Virology
Verified
Journal Article
Open access
Alireza MohebbiAlireza Mohebbi
Alireza Mohebbi
FAFatemeh Sana Askari
Fatemeh Sana Askari
ASAli Salehnia Sammak
Ali Salehnia Sammak
MEMohsen Ebrahimi
Mohsen Ebrahimi
ZNZahra Najafimemar
Zahra Najafimemar
Aim: Virus spike glycoprotein of SARS-CoV-2 is a good target for drug discovery. Objective: To examine the potential for druggability of spike protein for pharmacophore-based drug discovery and to ...